These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 2426823)
1. Beta-thromboglobulin content in megakaryocytes of patients with myeloproliferative diseases. Grossi A; Vannucchi AM; Rafanelli D; Filimberti E; Rossi Ferrini P Thromb Res; 1986 Aug; 43(3):367-74. PubMed ID: 2426823 [No Abstract] [Full Text] [Related]
2. The role of beta-catenin in chronic myeloproliferative disorders. Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646 [TBL] [Abstract][Full Text] [Related]
3. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648 [TBL] [Abstract][Full Text] [Related]
4. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms. Medinger M; Tzankov A; Kern J; Pircher A; Hermann M; Ott HW; Gastl G; Untergasser G; Gunsilius E Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717 [TBL] [Abstract][Full Text] [Related]
5. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders. Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485 [TBL] [Abstract][Full Text] [Related]
6. β-catenin and PPAR-γ levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study. Subotički T; Mitrović Ajtić O; Mićić M; Kravić Stevović T; Đikić D; Diklić M; Leković D; Gotić M; Čokić VP Ultrastruct Pathol; 2018; 42(6):498-507. PubMed ID: 30582392 [TBL] [Abstract][Full Text] [Related]
7. Immunological localisation of beta-thromboglobulin and platelet factor 4 in human megakaryocytes and platelets. McLaren KM; Pepper DS J Clin Pathol; 1982 Nov; 35(11):1227-31. PubMed ID: 6183294 [TBL] [Abstract][Full Text] [Related]
9. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms. Tadmor T; Bejar J; Attias D; Mischenko E; Sabo E; Neufeld G; Vadasz Z Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965 [TBL] [Abstract][Full Text] [Related]
10. Effect of aspirin on platelet 5-hydroxytryptamine and beta-thromboglobulin plasma levels in patients with myeloproliferative diseases. Viero P; Cortelazzo S; Bassan R; Barbui T Thromb Haemost; 1982 Oct; 48(2):125-6. PubMed ID: 6184841 [TBL] [Abstract][Full Text] [Related]
11. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F. Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702 [TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis. Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365 [TBL] [Abstract][Full Text] [Related]
13. Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. Ruberti S; Bianchi E; Guglielmelli P; Rontauroli S; Barbieri G; Tavernari L; Fanelli T; Norfo R; Pennucci V; Fattori GC; Mannarelli C; Bartalucci N; Mora B; Elli L; Avanzini MA; Rossi C; Salmoiraghi S; Zini R; Salati S; Prudente Z; Rosti V; Passamonti F; Rambaldi A; Ferrari S; Tagliafico E; Vannucchi AM; Manfredini R Leukemia; 2018 Feb; 32(2):438-449. PubMed ID: 28745329 [TBL] [Abstract][Full Text] [Related]
14. The spectrum of myeloproliferative disorders. Gilbert HS Med Clin North Am; 1973 Mar; 57(2):355-93. PubMed ID: 4570933 [No Abstract] [Full Text] [Related]
15. Clinical significance of beta-thromboglobulin in patients with high platelet count. Fabris F; Randi ML; Casonato A; Dal Bo Zanon R; Bonvicini P; Girolami A Acta Haematol; 1984; 71(1):32-8. PubMed ID: 6197855 [TBL] [Abstract][Full Text] [Related]
16. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Michiels JJ; Juvonen E Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350 [TBL] [Abstract][Full Text] [Related]
17. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function. Barbui T; Cortelazzo S; Viero P; Bassan R; Dini E; Semeraro N Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1593-9. PubMed ID: 6580171 [TBL] [Abstract][Full Text] [Related]
19. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders. Wehmeier A; Fricke S; Scharf RE; Schneider W Eur J Haematol; 1990 Oct; 45(4):191-7. PubMed ID: 2146144 [TBL] [Abstract][Full Text] [Related]
20. Megakaryocytes in cubital venous blood in patients with chronic myeloproliferative diseases. Tinggaard Pedersen N; Laursen B Scand J Haematol; 1983 Jan; 30(1):50-8. PubMed ID: 6573016 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]